International Assets Investment Management LLC Acquires 156,386 Shares of Progyny, Inc. (NASDAQ:PGNY)

International Assets Investment Management LLC raised its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 9,381.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 158,053 shares of the company's stock after acquiring an additional 156,386 shares during the quarter. Progyny comprises approximately 1.2% of International Assets Investment Management LLC's investment portfolio, making the stock its 11th biggest holding. International Assets Investment Management LLC owned approximately 0.16% of Progyny worth $5,876,411,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. BlackRock Inc. boosted its stake in shares of Progyny by 3.8% in the 1st quarter. BlackRock Inc. now owns 9,700,353 shares of the company's stock valued at $311,575,000 after purchasing an additional 353,499 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Progyny by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 8,157,604 shares of the company's stock valued at $277,522,000 after purchasing an additional 565,160 shares during the last quarter. Clearbridge Investments LLC boosted its stake in shares of Progyny by 2.7% in the 1st quarter. Clearbridge Investments LLC now owns 3,223,502 shares of the company's stock valued at $165,688,000 after purchasing an additional 86,249 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Progyny by 11.3% in the 1st quarter. Thrivent Financial for Lutherans now owns 2,885,980 shares of the company's stock valued at $92,698,000 after purchasing an additional 293,192 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Progyny by 19.4% during the 3rd quarter. Jennison Associates LLC now owns 2,706,454 shares of the company's stock worth $92,074,000 after acquiring an additional 438,932 shares during the last quarter. Institutional investors own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Leerink Partnrs reissued an "outperform" rating on shares of Progyny in a research note on Monday, February 26th. Cantor Fitzgerald reissued an "overweight" rating and set a $48.00 price objective on shares of Progyny in a research note on Wednesday, February 28th. SVB Leerink assumed coverage on shares of Progyny in a research note on Monday, February 26th. They set an "outperform" rating and a $49.00 price objective on the stock. KeyCorp reduced their price objective on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 28th. Finally, Truist Financial reduced their price objective on shares of Progyny from $47.00 to $46.00 and set a "buy" rating on the stock in a research note on Wednesday, February 28th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat, Progyny presently has an average rating of "Buy" and an average price target of $48.30.

Insider Activity

In other news, Chairman David J. Schlanger sold 71,272 shares of Progyny stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total value of $2,694,081.60. Following the sale, the chairman now directly owns 86,312 shares in the company, valued at $3,262,593.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Chairman David J. Schlanger sold 71,272 shares of Progyny stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total value of $2,694,081.60. Following the sale, the chairman now directly owns 86,312 shares in the company, valued at $3,262,593.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Michael E. Sturmer sold 2,260 shares of Progyny stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $40.00, for a total transaction of $90,400.00. Following the completion of the sale, the president now owns 158,532 shares in the company, valued at $6,341,280. The disclosure for this sale can be found here. Insiders have sold 186,517 shares of company stock worth $7,070,287 over the last ninety days. Insiders own 14.30% of the company's stock.

Progyny Price Performance

PGNY traded down $0.11 during trading on Friday, reaching $35.39. The company had a trading volume of 416,382 shares, compared to its average volume of 749,088. Progyny, Inc. has a 12 month low of $29.44 and a 12 month high of $44.95. The business's fifty day moving average price is $37.72 and its 200 day moving average price is $35.65. The company has a market cap of $3.42 billion, a P/E ratio of 57.08, a PEG ratio of 1.46 and a beta of 1.48.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. During the same quarter in the previous year, the firm posted $0.03 earnings per share. The business's revenue was up 26.0% on a year-over-year basis. As a group, sell-side analysts predict that Progyny, Inc. will post 0.7 EPS for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.